Europe — EMA
Palmeux (Paliperidone Palmitate)
Paliperidone palmitate, the active ingredient in Palme de, is a atypical antipsychotic presented as a long‑acting injectable suspension for intramuscular use.
Request sourcing
What is Paliperidone Palmitate?
Paliperidone palmitate, the active ingredient in Palme de, is a atypical antipsychotic presented as a long‑acting injectable suspension for intramuscular use. It is indicated for the maintenance treatment of schizophrenia in adult patients.
GNH USA supplies Palmeux as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.
What is Paliperidone Palmitate used for?
Palmeux is a long‑acting formulation of paliperidone palmitate that acts on dopamine‑type 2 (D2) and serotonin‑type 2A (5‑HT2A) receptors to stabilise psychotic symptoms. - Schizophrenia: Improves positive and negative symptom control and reduces relapse risk. - Schizoaffective disorder: Helps maintain mood stability and psychotic symptom control. - Bipolar I disorder (maintenance): Contributes to prevention of recurrence of manic episodes. - Maintenance therapy: Provides consistent plasma levels, reducing need for daily oral medication.
What are the side effects of Paliperidone Palmitate?
Adverse reactions reported with paliperidone palmitate span a range of frequencies.
Common Side Effects: - Injection site pain or erythema - Headache - Drowsiness or somnolence - Weight gain - Restlessness (akathisia) - Constipation
Serious or Rare Side Effects: - Neuroleptic malignant syndrome - Tardive dyskinesia - Severe hypotension - Hyperglycaemia or new‑onset diabetes - Seizures - Elevated prolactin with galactorrhoea or menstrual disturbances
What precautions apply to Paliperidone Palmitate?
When prescribing Palme us to patients, clinicians should consider several precautions. - Monitor blood pressure : Regular assessment of systolic and diastolic values. - Assess metabolic : Check faster and regular metabolic parameters including glucose and lipid ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ...... ... ... ... ... ...... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ......
--- t ewline
t ewline \n ewline ight ewline .... ... ... ... ... ... ... ... ......
